Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Pharmacokinetic interaction between nevirapine and darunavir with low‐dose ritonavir in HIV‐1‐infected patients

2009; Wiley; Volume: 68; Issue: 1 Linguagem: Inglês

10.1111/j.1365-2125.2009.03430.x

ISSN

1365-2125

Autores

Vanitha Sekar, Éric Lefebvre, Kris Mariën, Martine De Pauw, Tony Vangeneugden, Anton Pozniak, Richard M. W. Hoetelmans,

Tópico(s)

HIV Research and Treatment

Resumo

To investigate the pharmacokinetic interaction between darunavir/ritonavir (DRV/r) and nevirapine (NVP) in 19 HIV-infected patients.An open-label, randomized, crossover study. Patients received Treatment A [NVP 200 mg b.i.d. plus > or =2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)] and Treatment B [A plus DRV/r 300/100 mg b.i.d. (DRV oral solution)] or Treatment B2 [A plus DRV/r 400/100 mg b.i.d. (DRV tablet)] in two 14-day sessions.Mean NVP AUC(12h) increased by 27% [least square means ratio 1.27 (95% confidence interval 1.02, 1.58)]. Mean DRV and ritonavir exposures were similar to historical data. Co-administration was well tolerated.DRV/r and NVP have no clinically relevant interaction. No dose adjustments are required.

Referência(s)